Compare PKG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKG | ALNY |
|---|---|---|
| Founded | 1867 | 2002 |
| Country | United States | United States |
| Employees | 13600 | 115 |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 21.6B |
| IPO Year | 1999 | 2004 |
| Metric | PKG | ALNY |
|---|---|---|
| Price | $250.88 | $165.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 30 |
| Target Price | $269.22 | ★ $299.96 |
| AVG Volume (30 Days) | 665.7K | ★ 3.1M |
| Earning Date | 10-21-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | 6.98 | ★ 18.42 |
| Revenue | ★ $8,989,300,000.00 | $1,037,418,000.00 |
| Revenue This Year | $12.21 | $46.57 |
| Revenue Next Year | $8.81 | $19.91 |
| P/E Ratio | $35.95 | ★ $8.93 |
| Revenue Growth | 7.23 | ★ 22.88 |
| 52 Week Low | $191.50 | $149.18 |
| 52 Week High | $262.59 | $479.79 |
| Indicator | PKG | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 34.57 |
| Support Level | $221.41 | N/A |
| Resistance Level | $259.24 | $237.47 |
| Average True Range (ATR) | 6.60 | 10.41 |
| MACD | -0.65 | -0.83 |
| Stochastic Oscillator | 41.72 | 19.58 |
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.